Want to see KRRO full AI Analyst Report?
KRRO Stock Chart & Stats
$13.26
-$1.03(-2.68%)
At close: 4:00 PM EST
$13.26
-$1.03(-2.68%)
Day’s Range― - ―
52-Week Range$5.20 - $55.89
Previous CloseN/A
Volume28.02K
Average Volume (3M)106.02K
Market Cap
$180.24M
Enterprise Value$159.39
Total Cash (Recent Filing)$115.04M
Total Debt (Recent Filing)$42.21M
Price to Earnings (P/E)―
Beta2.81
Next Earnings
Nov 18, 2026EPS Estimate
-1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.01
Shares Outstanding14,725,646
10 Day Avg. Volume71,642
30 Day Avg. Volume106,024
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.46
Price to Sales (P/S)11.77
P/FCF Ratio-0.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.71Price Target Upside41.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.32
Revenue Forecast (FY)$300.00K
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline AdvancementAdvancing KRRO-121 from preclinical research toward human testing creates a durable clinical value inflection point and may validate Korro’s RNA-editing approach in rare metabolic disease.
Cash RunwayA cash runway extending into 2028 gives Korro time to execute clinical programs and generate evidence before needing additional capital, reducing near-term financing pressure.
Pipeline And Platform ExpansionAdding KRRO-111 broadens the pipeline beyond the lead program and demonstrates potential reuse of Korro’s RNA-editing platform across genetically driven liver diseases.
Bears Say
Persistent Cash BurnSustained cash outflows without positive cash generation require continued access to financing and increase the risk that future development will depend on external capital.
Deep Operating LossesLarge operating and net losses show that the business has not reached commercial scale, leaving profitability dependent on successful clinical development and eventual product launches.
Revenue ContractionWeak and inconsistent revenue provides limited internal funding for research and development, increasing reliance on the pipeline and making financial performance vulnerable to development timing.
Korro Bio News
KRRO FAQ
What was Korro Bio’s price range in the past 12 months?
Korro Bio lowest stock price was $5.20 and its highest was $55.89 in the past 12 months.
What is Korro Bio’s market cap?
Korro Bio’s market cap is $180.24M.
When is Korro Bio’s upcoming earnings report date?
Korro Bio’s upcoming earnings report date is Nov 18, 2026 which is in 76 days.
How were Korro Bio’s earnings last quarter?
Korro Bio released its earnings results on Aug 06, 2026. The company reported -$1.07 earnings per share for the quarter, beating the consensus estimate of -$1.338 by $0.268.
Is Korro Bio overvalued?
According to Wall Street analysts Korro Bio’s price is currently Undervalued.
Does Korro Bio pay dividends?
Korro Bio does not currently pay dividends.
What is Korro Bio’s EPS estimate?
Korro Bio’s EPS estimate is -1.26.
How many shares outstanding does Korro Bio have?
Korro Bio has 14,725,646 shares outstanding.
What happened to Korro Bio’s price movement after its last earnings report?
Korro Bio reported an EPS of -$1.07 in its last earnings report, beating expectations of -$1.338. Following the earnings report the stock price went up 5.391%.
Which hedge fund is a major shareholder of Korro Bio?
Currently, no hedge funds are holding shares in KRRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Korro Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.71 (41.13% Upside)
$18.71 (41.13% Upside)
Blogger Sentiment
Neutral
KRRO Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $78.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-46.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Korro Bio
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
KRRO Stock 12 Month Forecast
Average Price Target
$18.71
▲(41.13% Upside)
Technical Analysis
Assembly Biosciences
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Aura Biosciences Inc
―